References in periodicals archive ?
L-dopa delivers dopamine to the brain to relieve symptoms.
Louis, MO), 1 in 1x PBS and another in AcOH/CTAB, and 2 1 mg [mL.sup.-1] L-DOPA solutions (Tocris Bioscience, Bristol, United Kingdom), also in 1x PBS and AcOH/CTAB.
Results: Personality disturbances and dysexecutive functioning (dysexecutive symptoms, inhibition, social regulation) were significantly reduced post L-dopa treatment.
Conclusion: L-Dopa is an effective treatment for cortical dysfunctions, health related quality of life and fatigue in I-PD.
Experimental Groups and Treatment: All the animals received chronic intermittent intraperitoneal (ip) injections of either L-dopa or saline twice daily (at 9 a.m.
The concentration of L-dopa (substrate) was set 1.25 mM, and 120 [micro]L in a sodium phosphate buffer (pH 6.8) was used for testing in a 96-well plate.
Since sensitivity to catecholamines in the heart is increased in patients using L-Dopa, these agents, especially halothane, should be avoided in such patients.
A total number of 42 rats were used in this experiment, 21 days after the surgery, animals were randomly divided into three groups ( n = 14 each group): (a) sham group (sham-operated, treated with saline); (b) 6-OHDA group (6-OHDA-lesioned, also treated with saline); and (c) L-DOPA group (6-OHDA-lesioned, treated with L-DOPA).
Mushroom (Agaricus bisporus) tyrosinase (3393 units/mg) and L-3,4-dihydroxyphenylalanine (L-DOPA) were purchased from Sigma-Aldrich and maintained at temperatures below -10 [degrees]C.
Rolon M y col (2007) refieren que frente a cuadros extrapiramidales progresivos en la infancia, es oportuno realizar, antes de emprender estudios mas complejos, la prueba terapeutica con L-Dopa, ya que si mejora el cuadro confirma la enfermedad.
Furthermore, the animal model they used were all different; seven studies assessed the effect on healthy naive human and animals [26,29-31, 34], three used immobilization stress to decrease [42] or increase [23, 35] the activity of LC before acupuncture treatment, one used L-dopa induced hyperactivated bladder model [32],and finally one study used CFA-induced inflammatory pain model [27].
Then add 40 [micro]L of tyrosinase solutions (0.693 (2.5 U/mL), 1.386 (5 U/mL), 2.772 (10 U/mL), 5.544 (20 U/mL), 6.93 (25 U/mL), and 11.088 (40 U/mL) [micro]g/mL, resp.) in a sodium phosphate buffer at pH 6.8 (PBS) and 120 [micro]L of the 0.625 mM of L-dopa solution (dissolved in PBS).